Table 3.

Summary of fremanezumab RCTs

Study	Phase	Migraine/N	Study period	Primary outcome
NCT02025556 Bigal et al. (2015) [30]	II	HFEM N = 297	3 months	placebo: −3.46 225 mg: −6.27 (p < 0.001) 675 mg: −6.09 (p < 0.001)
NCT02621931 Silberstein et al. (2017) (HALO-CM) [31]	III	CM N = 1130	3 months	placebo: −2.5 225 mg: −4.6 (p < 0.001) 675 mg: −4.3 (p < 0.001)
NCT02629861 Dodick et al. (2018) (HALO-EM) [32]	III	EM N = 875	3 months	placebo: −2.2 225 mg: −3.7 (p < 0.001) 675 mg: −3.4 (p < 0.001)
NCT03308968 Ferrai et al. (2019) (FOCUS) [33]	III	EM, CM N = 838	3 months	placebo: −0.6 225 mg: −4.1 (p < 0.001) 675 mg: −3.7 (p < 0.001)

All studies required ≤ 2 classes of failed preventive treatments. Primary outcome was MMD reduction for all studies. Fremanezumab 225 mg dosages were given monthly, 675 mg dosages were given every 3 months

EM episodic migraine, HFEM high-frequency episodic migraine, CM chronic migraine, MMD mean monthly migraine day